<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03125889</url>
  </required_header>
  <id_info>
    <org_study_id>TP0131</org_study_id>
    <nct_id>NCT03125889</nct_id>
  </id_info>
  <brief_title>Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia II</brief_title>
  <acronym>AHA II</acronym>
  <official_title>Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PROCEPT BioRobotics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PROCEPT BioRobotics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-arm prospective, interventional clinical trial to evaluate the safety and
      performance of obtaining hemostasis following prostate resection using the AQUABEAM for
      treatment of LUTS resulting from BPH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROCEPT BioRobotics has developed the AQUABEAM, a personalized image-guided waterjet
      resection system that utilizes a high-velocity saline stream to resect and remove prostate
      tissue in males suffering from LUTS due to BPH. The AQUABEAM System is intended for the
      resection and removal of prostate tissue in patients experiencing lower urinary tract
      symptoms (LUTS).The primary objective of this study is to evaluate the safety and performance
      of obtaining hemostasis with catheters following prostate resection using AQUABEAM for the
      treatment of LUTS resulting from BPH. Up to 50 participants will be included in the trial at
      one clinical study site. All patients will be followed up for 30 days for safety assessment
      prior to study exit. The trial is a single-arm prospective, interventional clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2017</start_date>
  <completion_date type="Actual">July 7, 2017</completion_date>
  <primary_completion_date type="Actual">April 18, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completion of the intended surgical procedure with adequate hemostasis</measure>
    <time_frame>7 days post-op</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who return to the OR for bleeding treatment or requires transfusion</measure>
    <time_frame>7 days post-op</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatment with the AquaBeam System to remove prostatic tissue.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AquaBeam System</intervention_name>
    <description>The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  BPH symptoms

        Exclusion Criteria:

          -  Serious concurrent medical conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Muljibhai Patel Urological Hospital</name>
      <address>
        <city>Nadiad</city>
        <state>Gujarat</state>
        <zip>387001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Image-guided</keyword>
  <keyword>BPH</keyword>
  <keyword>Aquablation</keyword>
  <keyword>AQUABEAM</keyword>
  <keyword>LUTS</keyword>
  <keyword>Tissue resection</keyword>
  <keyword>Robotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

